source
- Genentech pays $45M upfront to DualityBio for ADC platform targeting resistant cancersGenentech has agreed to pay DualityBio $45 million upfront for rights to its antibody‑drug conjugate (ADC) technology, with the agreement offering more than $1 billion in potential milestone paymen…
- AstraZeneca and Ionis report unexpected failure of heart disease drug in trialAstraZeneca and Ionis disclosed that their collaborative heart disease drug did not meet primary endpoints in a recent trial, marking a surprise setback. The companies detailed the trial results,…